• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

    4/21/25 8:00:00 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMMB alert in real time by email

    TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025®; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology's annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.

    DDW25, May 3-6, 2025, San Diego, USA
      
    Date:May 4, 2025
    Time:4:00 - 5:30pm PDT
    Format: Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis (PSC): The Spring Study
    Presenter:Paul Pockros, MD, Director, Liver Disease Scripps Clinic and SC Liver Disease Consortium
    Session:Liver & Biliary Section Distinguished Abstract Plenary
    Information:https://ddw.org/
      
    EASL 2025, May 7-10, 2025, Amsterdam, Netherlands
      
    Date:May 8, 2025
    Time: 8:30-17:30 CEDT
    Format:Poster presentation: CM-101 impacts disease biomarkers in primary sclerosing cholangitis: assessment of the SPRING study pharmacokinetics and pharmacodynamics
    Presenter:Adi Mor, PhD, co-founder and CEO, Chemomab
    Session:Immune-mediated and cholestatic disease: Clinical aspects; Abstract #1255
    Information:  https://www.easlcongress.eu
      
    EASL 2025, May 7-10, 2025, Amsterdam, Netherlands
      
    Date: May 9, 2025
    Time: 8:30-17:30 CEDT
    Format:Poster presentation: CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes
    Presenter:  Adi Mor, PhD, co-founder and CEO, Chemomab
    Session: Immune-mediated and cholestatic: Experimental and pathophysiology; Abstract #1243
    Information:https://www.easlcongress.eu
      
    BSG Live'25, June 23-26, 2025, Glasgow, UK
      
    Date:June 23-26, 2025
    Time:TBD
    Format: Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, in patients with primary sclerosing cholangitis: results from SPRING Study 
    Presenter: Douglas Thorburn, MD, Divisional Clinical Director for Liver and Digestive Health at the Royal Free London NHS Trust and Professor of Hepatology in the Institute for Liver and Digestive Health at UCL
    Session:Liver
    Information:https://live.bsg.org.uk/

         

    About Chemomab Therapeutics Ltd.

    Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab's nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: chemomab.com.

      

    Contacts:

    Media and Investors:

    Barbara Lindheim

    Consulting Vice President, Investor & Public Relations, Strategic Communications

    Phone: +1 917-355-9234

    [email protected]

    [email protected]



    Primary Logo

    Get the next $CMMB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CMMB

    DatePrice TargetRatingAnalyst
    5/13/2024$4.00Buy
    Maxim Group
    5/6/2024$6.00Perform → Outperform
    Oppenheimer
    12/19/2023$7.00Buy
    ROTH MKM
    3/10/2022$30.00 → $20.00Outperform
    Oppenheimer
    12/7/2021$30.00Buy
    Aegis Capital
    More analyst ratings

    $CMMB
    SEC Filings

    See more
    • SEC Form 6-K filed by Chemomab Therapeutics Ltd.

      6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

      7/1/25 4:05:42 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Chemomab Therapeutics Ltd.

      6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

      5/27/25 4:05:25 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Chemomab Therapeutics Ltd.

      6-K - Chemomab Therapeutics Ltd. (0001534248) (Filer)

      5/15/25 8:00:10 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Chemomab Therapeutics with a new price target

      Maxim Group initiated coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $4.00

      5/13/24 8:28:18 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Chemomab Therapeutics from Perform to Outperform and set a new price target of $6.00

      5/6/24 7:45:06 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Chemomab Therapeutics with a new price target

      ROTH MKM resumed coverage of Chemomab Therapeutics with a rating of Buy and set a new price target of $7.00

      12/19/23 6:47:13 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

      SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC Disease Progression TEL AVIV, Israel and GLASGOW, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) i

      6/30/25 8:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

      —Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue— TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported that it has obtained confirmation from the FDA on two significant development milestones as the company continues to finalize the nebokitug Phase 3 program. As part of the FDA End-of-Phase 2 (EOP2) review process, Ch

      6/11/25 8:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

      —New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041— —Further Expands Protections Provided by Nebokitug's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and Additional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (NASDAQ:CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections in China and Ru

      6/3/25 8:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Darvish Nissim

      4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

      7/5/23 5:48:43 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Quigley Jill M.

      4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

      6/20/23 6:03:03 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fatal Sigal

      4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)

      6/16/23 4:03:05 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Leadership Updates

    Live Leadership Updates

    See more
    • Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

      TEL AVIV, Israel, Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones, MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than 15 years of leadership experience in biopharmaceutical research, clinical development, corporate strategy and entrepreneurship, organizational development and team-building, technology transfer and licensing and acquisitions. He will be responsible for spearheading the corpor

      11/30/22 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer

      TEL AVIV, Israel, Nov. 14, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Matthew Frankel, MD, MBA as Chief Medical Officer (CMO) and Vice President of Drug Development. "We believe Dr. Frankel's wealth of experience across all aspects of clinical development and medical affairs, along with his outstanding performance in helping to bring biologic and

      11/14/22 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

      ─Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President  of Clinical Development─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. "Ch

      8/12/22 6:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Financials

    Live finance-specific insights

    See more
    • Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

      TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd.                                                     

      10/30/24 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

      TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at [email protected]. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company

      8/12/24 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

      First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically Significant Improvements in Liver Stiffness, a Well-Validated Biomarker of Disease Progression in PSC Treatment with CM-101 Led to Statistically Significant Improvements in Pruritis and Improvements in Total Bilirubin and Liver Function Tests Positive Phase 2 Data Paves Way f

      7/25/24 7:00:00 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

      SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

      11/29/24 3:04:59 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

      SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

      11/21/24 10:59:28 AM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

      SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

      9/16/24 4:34:03 PM ET
      $CMMB
      Biotechnology: Pharmaceutical Preparations
      Health Care